Browsing by Author "Pujana, Miguel Angel"

Sort by: Order: Results:

  • Serra Musach, Jordi; Capdevila Busquets, Eva; Jaeger, Samira; Aloy, Patrick, 1972-; Pujana, Miguel Angel (BioMed Central, 2016)
    Background: Cancer patients often show no or only modest benefit from a given therapy. This major problem in oncology is generally attributed to the lack of specific predictive biomarkers, yet a global measure of cancer ...
  • Çubut, Cankut; Hidalgo, Marta R.; Amadoz, Alicia; Rian, Kinza; Salavert, Francisco; Pujana, Miguel Angel; Mateo, Francesca; Herranz Ors, Carmen, 1992-; Carbonell-Caballero, Jose; Dopazo, Joaquín (Nature Research, 2019)
    In spite of the increasing availability of genomic and transcriptomic data, there is still a gap between the detection of perturbations in gene expression and the understanding of their contribution to the molecular ...
  • Solé, Xavier; Hernández, Pilar; López de Heredia, Miguel de; Armengol i Dulcet, Lluís; Rodríguez Santiago, Benjamín; Gómez, Laia; Maxwell, Christopher A.; Aguilo, Fernando; Condom, Enric; Abril, Jesús; Pérez Jurado, Luis Alberto; Estivill, Xavier, 1955-; Nunes, Virginia; Capellá, Gabriel; Gruber, Stephen B.; Moreno, Víctor; Pujana, Miguel Angel (BioMed Central, 2008)
    Background: Germline genetic variation is associated with the differential expression of many human genes. The phenotypic effects of this type of variation may be important when considering susceptibility to common genetic ...
  • Herranz Ors, Carmen, 1992-; Gómez Moruno, Antonio; Pujana, Miguel Angel (EMBO Press, 2021)
    Inhibition of mTOR is the standard of care for lymphangioleiomyomatosis (LAM). However, this therapy has variable tolerability and some patients show progressive decline of lung function despite treatment. LAM diagnosis ...
  • Palomero, Luis; Mereu, Elisabetta; Pujana, Miguel Angel (Elsevier, 2020)
    Proper immune system function hinders cancer development, but little is known about whether genetic variants linked to cancer risk alter immune cells. Here, we report 57 cancer risk loci associated with differences in ...
  • Maxwell, Christopher A.; Guigó Serra, Roderic; Curado, Joao; Tilgner, Hagen, 1980-; Pujana, Miguel Angel (Public Library of Science (PLoS), 2011)
    Differentiated mammary epithelium shows apicobasal polarity, and loss of tissue organization is an early hallmark of breast carcinogenesis. In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal ...
  • Sebestyén, Endre; Singh, Babita, 1986-; Miñana Gómez, Belén; Pagès Pinós, Amadís; Mateo, Francesc; Pujana, Miguel Angel; Valcárcel, J. (Juan); Eyras Jiménez, Eduardo (Cold Spring Harbor Laboratory Press (CSHL Press), 2016)
    Alternative splicing is regulated by multiple RNA-binding proteins and influences the expression of most eukaryotic genes. However, the role of this process in human disease, and particularly in cancer, is only starting ...
  • Mateo, Francesca; López Bigas, Núria; Pujana, Miguel Angel (Nature Publishing Group, 2017)
    Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition ...
  • Aguilar, Helena; Caizzi, Livia; Di Croce, Luciano; Pujana, Miguel Angel (BioMed Central, 2014)
    Introduction: Endocrine therapies targeting cell proliferation and survival mediated by estrogen receptor α (ERα) are among the most effective systemic treatments for ERα-positive breast cancer. However, most tumors initially ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking